ArQule Gets $30 Million Up Front From Kyowa In Oncology Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement with Japanese firm to develop and commercialize Phase I c-Met inhibitor ARQ 197 in Asia provides much-needed cash infusion.
You may also be interested in...
ArQule Gets Early-Stage Cancer Program Back From Daiichi
The Japanese pharma has elected to return rights to an early-stage cancer development program to ArQule, but the biotech reassured investors the two companies will continue to move forward on their beleaguered late-stage oncology endeavor.
ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi-Sankyo
Two deals bring the biotech $75 million upfront, plus research and clinical development funding.
ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi-Sankyo
Two deals bring the biotech $75 million upfront, plus research and clinical development funding.